首页> 外文OA文献 >Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

【2h】

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

机译：达沙替尼在伊马替尼耐药或不耐受的慢性粒细胞白血病加速期患者中引起明显的血液学和细胞遗传学反应

页面导航

著录项
相似文献
相关主题

著录项

作者
Guilhot F; Apperley J; Kim D; Bullorsky E; Baccarani M; Roboz G; Amadori S; De Souza C; Lipton J; Hochaus A; Heim D; Larson R; Branford S; Muller M; Agarwal P; Gollerkeri A; Talpaz M;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [J] . AbbottB.L. Clinical therapeutics . 2012 ,第2期

机译：达沙替尼：从对伊马替尼耐药或不耐受的慢性粒细胞白血病患者的治疗到新诊断的慢性期慢性粒细胞白血病患者的治疗
2. Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase [J] . Koiti Inokuchi, Takashi Kumagai, Eri Matsuki, Journal of clinical and experimental hematopathology : . 2014 ,第3期

机译：达沙替尼治疗开始后1或3个月的分子反应效率可预测在慢性期的伊马替尼耐药或伊马替尼耐药的日本慢性粒细胞白血病患者对达沙替尼的反应有所改善
3. Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase [J] . Koiti Inokuchi, Takashi Kumagai, Eri Matsuki, Journal of clinical and experimental hematopathology : . 2014 ,第3期

机译：达沙替尼治疗开始后1或3个月的分子反应功效可预测在慢性期的伊马替尼耐药或伊马替尼耐药的日本慢性粒细胞白血病患者对达沙替尼的反应有所改善
4. Plasma metabolite profiling of chronic myeloid leukemia patients [C] . Radana Karlikova, Marcela Hrda, Jitka Siroka, International Mass Spectrometry Conference . 2014

机译：慢性骨髓白血病患者的血浆代谢物分析
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study [O] . Giuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, -1

机译：在第3阶段研究后2年后2年后在伊马替尼抗性或伊马替尼抗性或伊马替尼 - 不耐受慢性骨髓性白血病中的达司
7. Budget Impact Analysis of Dasatinib in Imatinib-Resistant Or-Intolerant Patients with Chronic Phase Chronic Myeloid Leukemia (Cml-Cp) in the Chinese Setting [O] . B Wu 2016

机译：乳氨酸含量耐慢性期慢性骨髓白血病（CML-CP）中达沙替尼的预算冲击分析

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

著录项

相似文献

相关主题

期刊订阅